Comparative Pharmacology
Head-to-head clinical analysis: GRIS PEG versus M ZOLE 3 COMBINATION PACK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GRIS PEG versus M ZOLE 3 COMBINATION PACK.
GRIS-PEG vs M-ZOLE 3 COMBINATION PACK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Griseofulvin binds to and disrupts microtubule function by interfering with the polymerization of tubulin, thereby inhibiting fungal cell mitosis and nucleic acid synthesis.
Miconazole inhibits fungal CYP450 14α-demethylase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity. Zinc pyrithione inhibits fungal growth by disrupting membrane transport and inhibiting energy metabolism.
For tinea capitis and other dermatophyte infections: 500 mg oral daily as a single dose or in divided doses. For more severe infections, up to 1 g daily in divided doses.
A single oral dose of 3 tablets (M-ZOLE 3 COMBINATION PACK) as a one-time treatment.
None Documented
None Documented
Terminal elimination half-life 14-24 hours. With continuous therapy, time to steady-state is ~3-5 days.
Terminal elimination half-life 20-30 hours in healthy adults; prolonged in renal impairment (up to 40-50 hours) and hepatic impairment
Primarily renal (as glucuronide conjugates): ~80%; fecal/biliary: ~10-15%; unchanged drug <1%.
Renal: ~70-80% as unchanged drug and metabolites; biliary/fecal: ~20%
Category C
Category C
Antifungal
Antifungal